PVR and glioblastoma: Engineered iNK cells were then challenged in vitro with GBM cell lines expressing or lacking CD155 (generated via CRISPR/Cas9 knockout) and/or CD73 in cytolysis assays and with GBM43 WT cells for degranulation and cytokine production.